Results 221 to 230 of about 3,900,144 (339)

Psychotropic drug treatment for agitated behaviour in dementia: what if the guideline prescribing recommendations are not sufficient? A qualitative study. [PDF]

Age Ageing, 2022
Dijk MT, Tabak S, Hertogh CMPM, Kok RM, van Marum RJ, Zuidema SU, Sizoo EM, Smalbrugge M.   +7 more
europepmc   +1 more source

Psychotropic drug-induced adverse drug reactions in 462,661 psychiatric inpatients in relation to age: results from a German drug surveillance program from 1993-2016. [PDF]

Ann Gen Psychiatry
Seifert J, Reinhard MA, Bleich S, Erfurth A, Greil W, Toto S, Grohmann R, Glocker C.   +7 more
europepmc   +1 more source

Psychotropic drug abuse in pregnancy and its impact on child neurodevelopment: A review. [PDF]

World J Clin Pediatr, 2022
Etemadi-Aleagha A, Akhgari M.
europepmc   +1 more source

What's the point [PDF]

, 2005
Jones, M
core   +2 more sources

Toxicokinetic modelling of the synthetic cannabinoid 5F‐MDMB‐P7AICA and its main metabolite in pigs following pulmonary administration

British Journal of Clinical Pharmacology, EarlyView.
Aims Since their emergence on the drug market, synthetic cannabinoids (SC) are still gaining increasing importance in forensic toxicology. The representatives of the so‐called new psychoactive substances have in common that they have not undergone preclinical safety studies. Hence, knowledge on toxicokinetic (TK) data is sparse.
Adrian A. Doerr, Christiane Dings, Omar Zaher, Frederike Nordmeier, Nadja Walle, Matthias W. Laschke, Michael D. Menger, Peter H. Schmidt, Markus R. Meyer, Thorsten Lehr, Nadine Schaefer   +10 more
wiley   +1 more source

Prolonged increase in psychotropic drug use among young women following the COVID-19 pandemic: a French nationwide retrospective study. [PDF]

BMC Med
Lamer A, Saint-Dizier C, Levaillant M, Hamel-Broza JF, Ayed E, Chazard E, Bubrovszky M, D'Hondt F, Génin M, Horn M.   +9 more
europepmc   +1 more source

Importance of early weight changes to predict long-term weight gain during psychotropic drug treatment.

Journal of Clinical Psychiatry, 2015
F. Vandenberghe, M. Gholam-Rezaee, N. Saigí-Morgui, A. Delacrétaz, E. Choong, A. Solida-Tozzi, S. Kolly, J. Thonney, Sylfa Fassassi Gallo, A. Hedjal, A. Ambresin, A. von Gunten, P. Conus, C. Eap   +13 more
semanticscholar   +1 more source

Safety pharmacology of acute mescaline administration in healthy participants

British Journal of Clinical Pharmacology, EarlyView.
Aims Psychedelics, including mescaline, may serve as novel treatments for depression and anxiety. However, data is scarce on the safety of mescaline. Methods The present pooled analysis included two double‐blind, randomized, placebo‐controlled studies with a total of 48 participants and 96 mescaline administrations. Single oral‐dose administrations (n =
Aaron Klaiber, Mélusine Humbert‐Droz, Laura Ley, Yasmin Schmid, Matthias E. Liechti   +4 more
wiley   +1 more source

Using sleep to enhance exposure treatment for anxious children: A pilot study

British Journal of Clinical Psychology, EarlyView.
Abstract Objectives: Exposure therapy is a well‐established treatment for anxiety disorders in children; however, many young people do not fully respond to treatment. Advances in strategies to enhance extinction learning from exposure therapy are urgently needed.
Ella L. Oar, Ronald M. Rapee, Cassie H. Lavell, Allison G. Harvey, Thomas H. Ollendick   +4 more
wiley   +1 more source

A Kpna1-deficient psychotropic drug-induced schizophrenia model mouse for studying gene-environment interactions. [PDF]

Sci Rep
Nomiya H, Sakurai K, Miyamoto Y, Oka M, Yoneda Y, Hikida T, Yamada M.   +6 more
europepmc   +1 more source